Novartis Kisqali cuts risk of death by ~20% in early breast cancer, six-year NATALEE data show

Novartis announced six-year follow-up data from its Phase III NATALEE study showing Kisqali (ribociclib) plus endocrine therapy reduces the risk of death by approximately 20% versus endocrine therapy alone in patients with Stage II and III HR+/HER2- early breast cancer at high risk of recurrence.

Detected & updated continuously · Source: Nebula